Literature DB >> 11864344

International multicenter investigation of LB20304, a new fluoronaphthyridone.

Annik F. Hohl1, Reno Frei, Verena Pünter, Alexander von Graevenitz, Cynthia Knapp, John Washington, David Johnson, Ronald N. Jones.   

Abstract

Entities:  

Year:  1998        PMID： 11864344     DOI： 10.1111/j.1469-0691.1998.tb00057.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


× No keyword cloud information.
  11 in total

1.  Antipneumococcal activities of gemifloxacin compared to those of nine other agents.

Authors:  T A Davies; L M Kelly; G A Pankuch; K L Credito; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Multiple-dose pharmacokinetics and tolerability of gemifloxacin administered orally to healthy volunteers.

Authors:  A Allen; E Bygate; M Vousden; S Oliver; M Johnson; C Ward; A Cheon; Y S Choo; I Kim
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  T A Davies; L M Kelly; D B Hoellman; L M Ednie; C L Clark; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Activities of gemifloxacin (SB 265805, LB20304) compared to those of other oral antimicrobial agents against unusual anaerobes.

Authors:  E J Goldstein; D M Citron; C Vreni Merriam; K Tyrrell; Y Warren
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

5.  Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacin.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; Deep Kwatra; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2011-08-16       Impact factor: 5.875

6.  Spectrofluorimetric methods for the determination of gemifloxacin in tablets and spiked plasma samples.

Authors:  Serife Evrim Kepekci Tekkeli; Armağan Önal
Journal:  J Fluoresc       Date:  2010-10-28       Impact factor: 2.217

7.  Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers.

Authors:  A Allen; E Bygate; S Oliver; M Johnson; C Ward; A J Cheon; Y S Choo; I C Kim
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

8.  In vitro activity of gemifloxacin (SB 265805) against anaerobes.

Authors:  E J Goldstein; D M Citron; Y Warren; K Tyrrell; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

9.  A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research Group.

Authors:  D J Hoban; S K Bouchillon; J A Karlowsky; J L Johnson; D L Butler; L A Miller; J A Poupard
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

10.  A Validated Reverse Phase-Ultra-Performance Liquid Chromatography Method for the Determination of Gemifloxacin Mesylate in Bulk and its Pharmaceutical Preparation.

Authors:  Hebatallah A Wagdy; Mohamed Tarek; Ahmed Amer; Menna Gamal; Mohey Elmazar
Journal:  Turk J Pharm Sci       Date:  2018-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.